APP Pharmaceuticals releases preservative-free Methotrexate; Ranbaxy selling generic Lipitor in Europe;

> APP Pharmaceuticals ($APPX), which two weeks ago received FDA approval to make preservative-free Methotrexate at its manufacturing facility in Melrose Park, IL, has released 35,000 vials of Methotrexate Injection, USP, and 10,000 vials of preservative-free Methotrexate Injection, USP, which should soon be available to clinicians to ease shortage issues. Story

> Per its agreement with Pfizer ($PFE), Ranbaxy Laboratories ($RANBXY.NS) is selling a generic version of Lipitor in Germany, Italy, Sweden and the Netherlands. Story

> Endo Pharmaceuticals Holdings ($ENDP), maker of the Opana ER painkiller, will ask shareholders to approve a name change to Endo Health Solutions Inc. Release

> Merck KGaA ($MRK.DE) has donated to the Zambian Health Ministry 5 mobile labs to be used to detect counterfeit medications. Release  

> Ann Arbor, MI.-based Rubicon Genomics, has selected Velesco Pharmaceutical Services, which has a 10,000 square foot manufacturing facility in nearby Kalamazoo, MI, to manufacture breast cancer diagnostics kits Rubicon is providing to Agendia, a molecular diagnostics company. Release  

> Chemist Cheng Yi Liang, who worked for the FDA's Center for Drug Evaluation and Research, was sentenced to 5 years in prison for trading on insider information to make $3.78 million. Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.